2024 BioSymposium sponsors – Innovating antibody drug conjugates: From mechanisms to market
State Government of Victoria
Web djsir.vic.gov.au/health-tech
Email medtech.pharma@ecodev.vic.gov.au
About us
Victoria is home to world-class health technology companies and is a preferred location for many global leaders including CSL, Moderna, BioNTech, Illumina, Telix Pharmaceuticals and Pfizer. International companies partner with Victoria for its outstanding strengths in commercial product development, its cost-competitive environment for basic discovery, clinical and commercial research, and its strong collaborative networks and supportive government.
Victoria is a global leader in health technologies research and manufacturing, delivering a sector value add of $5.5 billion in 2022. Victoria’s research and development capabilities include: infectious disease and diagnostics; digital health and patient monitoring; cancer; cell therapies and regenerative medicine; neuroscience; paediatrics.
Victoria’s health technologies ecosystem is supported by its skilled and multicultural talent pool, favourable regulatory and research and development environment, and world leading infrastructure - all backed by the Victorian Government’s long-term investment into the sector.
The Victorian Government has recognised health technologies as a priority industry sector for more than two decades and is committed to working with business to grow the research and innovation ecosystem. The Victorian Government has a global network of 23 international business offices, actively working with companies worldwide to assist them to partner with Victoria to develop novel health technologies and services.
We look forward to connecting with you.
For more information on how the Victorian Government can support your business, please visit our website.
CSIRO
Web www.csiro.au
Phone 1300 363 400
About us
CSIRO’s vision is to create a better future for Australia by solving the greatest challenges through innovative science and technology.
We work with biomedical companies to deliver new medical treatments and technologies that benefit millions of people in Australia and overseas, helping them live longer, healthier and more productive lives.
CSIRO is one of the largest multidisciplinary science organisations in the world. Our biomedical work supports local businesses and the broader research community across preclinical, manufacturing, devices and sensors, diagnostics and eHealth.
Moderna
Web modernatx.com
Phone 1800 344 018
Email WeCare@modernatx.com
About us
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company is developing a range of new medicines and vaccines.
Moderna's mRNA platform is enabling the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly shape the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com.au
FB Rice
Phone +61 3 8618 4100
Email contact@fbrice.com.au
About us
Founded over 70 years ago, FB Rice has become Australia's most trusted intellectual property firm, with offices nationwide and a well-established presence in New Zealand and South-East Asia.
Today, we bring world-leading expertise across biotechnology, chemistry, computer and electrical sciences, engineering, and medical devices. With a focus on integrity and determination, we are committed to helping our clients achieve their goals. Our distinct advantage lies in our independent status—without external obligations, our sole focus is on the success of our clients. This dedication is reflected in our accolades, including 15 Australian Client Choice Awards and seven consecutive titles as Best Specialist IP Firm.
With decades of experience, we understand that the right advice can be the difference between success and frustration. Our diverse, multidisciplinary team consistently goes the extra mile to leverage IP for maximum commercial impact.
At FB Rice, we nurture and grow best-in-class attorneys who excel not only in intellectual property but also in understanding our clients' environments. We tailor IP advice and strategy to each client's unique needs, always striving to provide exceptional service. Our expertise, coupled with a commitment to making our clients feel comfortable and respected at every stage, sets us apart. We build partnerships based on trust by being open, approachable, and completely focused on our clients’ needs.
At FB Rice, we champion innovation and create value.
Marsh
Web https://www.marsh.com/au/home.html
Email Louise.Clarke@marsh.com
Phone +61 409 617 945
About us
Marsh is the world’s leading insurance broker and risk advisor. Thanks to its innovative, customer-led approach and deep sector experience, Marsh adds value to clients beyond just insurance, through comprehensive risk profile assessments and clear, easy-to-understand advice. Our comprehensive suite of services includes insurance coverage, risk assessment and mitigation strategies, claims management, and ongoing support to help you navigate the complex and ever-changing landscape of the life sciences industry.
Life sciences companies have the opportunity to truly change the world, but success depends on how well certain emerging and traditional risks are managed. Marsh’s specialists can support your business objectives with risk strategies that promote resilience and competitiveness. From program placement to claims management and risk consulting, we understand the bespoke challenges faced by your business and to your risks, whether you are in the pharmaceutical, biotechnology, medical device and supply, or contract research sector. As you manage complex regulatory requirements and unique market conditions, we will draw on our deep knowledge of your key risks to offer solutions that support your vision.
From a nimble start-up with a bold idea to a listed company bringing in revenue from overseas, success is dependent on knowing the right levers to pull and when. Marsh’s dedicated life sciences team can help you navigate the relevant requirements and map out risk strategies and approaches — even as new issues emerge.
Radium Capital
Contact Tim Hynes
Email tim.hynes@radiumcapital.com.au
Phone +61 3 9917 8968
About us
Radium Capital is Australia’s market leader in Research & Development (R&D) financing. We believe businesses with R&D should have access to capital when they need it. So, we created Radium Advances to provide quick, easy and early access to up to 80% of expected R&D tax incentive refunds.
Radium Advances are available as a one-off cash injection, or can be used strategically multiple times throughout the year to smooth cash flow. The more you use Radium Advances the more your R&D benefits. Under a quarterly model, for the same expenditure, you can;
- boost your R&D spend by 50% or reduce your outlay by 33%
- reinvest up to 150% of R&D expenditure back into R&D
We are passionate about supporting Australian innovators and since our inception in 2017, we have provided over $750m of R&D funding to Australian innovation businesses.
Find out how innovators across Australia are using non-dilutive R&D financing to accelerate growth, attract other sources of funding and smooth cash flow at radiumcapital.com.au
SeerPharma Pty Ltd
Contact Biju Kishor
Email biju.kishor@seerpharma.com.au
About us
SeerPharma is a team of consultants that provide advice, training, software solutions from MasterControl, and contract labour resources to pharmaceutical, medical device and life science companies in the Asia-Pacific region, on matters of Quality Assurance and GMP compliance. We have been serving our clients in the Asia-Pacific region for over 30 years from our offices in Australia and Singapore, and are also able to provide assistance in Europe through our affiliate in the UK.
Our team of consultants have extensive experience working with clients supplying or looking to enter the supply chain of a therapeutic product. We work with organisations looking to ensure that their facilities, equipment, quality systems and processes are compliant with FDA, PIC/S, TGA, WHO, ISO, ICH and other GxP regulations and standards that apply to their product(s).
Through our work we aim to “Advance Quality and GMP Best Practices in the APAC region” for the Pharmaceutical and Medical Device Industry.
Category: BioMelbourne News
BioMelbourne Network respectfully acknowledges the Traditional Custodians of the unceded lands and waters of Victoria: the Bunurong, Gunaikurnai and Wurundjeri peoples, on which the BioMelbourne Network and our Victorian members work, and as well as the lands and waters of our members further afield. We pay respect to their Elders past and present. As Australia’s first scientists, we acknowledge the significant contribution that they and other Aboriginal and Torres Strait Islander people have made and continue to make to the research and knowledge systems that inform our community and our sector.
We acknowledge that Aboriginal and Torres Strait Islander people continue to live in a spiritual and sacred relationship with this country and recognise our responsibility to continue to work towards reconciliation.
